New tyrosine kinase 2 inhibitor shows Promising Safety and Efficacy in Atopic Dermatitis: JAMA
A new study published in the Journal of the American Medical Association showed that in the treatment of atopic dermatitis (AD), once-daily oral ICP-332, a tyrosine kinase 2 inhibitor, showed…